Related Experiment Video
Updated: May 7, 2026

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method
Published on: October 23, 2018
Profibrotic effect of miR-33a with Akt activation in hepatic stellate cells
Zhuo-Jian Li1, Pai-Huai Ou-Yang, Xing-Peng Han
1College of Life Science and Technology, Jinan University, Guangzhou, Guangdong 510632, China.
Abstract:
MicroRNAs (miRNAs) attract more attention in the pathophysiology of liver fibrosis and miR-33a has been previously demonstrated as involved in the regulation of cholesterol and lipid metabolism. Transforming growth factor-beta1 (TGF-β1) is generally accepted to be the main stimulating factor in the hepatic stellate cells (HSCs) activation, which plays an important role in hepatic fibrosis. However, the involvement and underlying mechanism of miR-33a and its role in TGF-β1-induced hepatic fibrogenesis remains unknown. Here, we investigate the role of miR-33a in the activation of immortalized human HSCs, Lx-2 cells. Our findings have shown that the expression of miR-33a with its host gene sterol regulatory element-binding protein 2 (SREBP2) was more highly expressed in activation of Lx-2 cells than in quiescent cells. The expression of miR-33a on TGF-β1-induced HSCs activation may be modulated via the activation of PI3K/Akt pathway. In addition, miR-33a significantly correlated with TGF-β1-induced expression of α1 (I) collagen (Col1A1) and α-SMA in HSCs. Bioinformatics analyses predict that peroxisome proliferator activated receptor-alpha (PPAR-α) is the potential target of miR-33a. We further found that anti-miR-33a significantly increases target gene PPAR-α mRNA and protein level, suggesting that miR-33a involved in HSCs function might be modulated by targeting PPAR-α. Finally, our results indicate that the expression of miR-33a increased with the progression of liver fibrosis. These results suggested that anti-miR-33a inhibit activation and extracellular matrix production, at least in part, via the activation of PI3K/Akt pathway and PPAR-α and anti sense of miR-33a may be a novel potential therapeutic approach for treating hepatic fibrosis in the future.
Insights
MicroRNA-33a (miR-33a) expression increases with liver fibrosis progression. Inhibiting miR-33a may offer a new therapeutic strategy for liver fibrosis by modulating hepatic stellate cell activation and extracellular matrix production.
Area of Science:
- Hepatology
- Molecular Biology
- Biochemistry
Background:
- MicroRNAs (miRNAs) are implicated in liver fibrosis pathogenesis.
- miR-33a regulates lipid metabolism and its role in liver fibrosis is unclear.
- Transforming growth factor-beta1 (TGF-β1) is a key driver of hepatic stellate cell (HSC) activation in liver fibrosis.
Purpose of the Study:
- To investigate the role and mechanism of miR-33a in TGF-β1-induced hepatic fibrogenesis.
- To explore miR-33a's involvement in HSC activation and extracellular matrix production.
- To assess the therapeutic potential of targeting miR-33a in liver fibrosis.
Main Methods:
- Studied miR-33a expression in activated human HSCs (Lx-2 cells).
- Investigated the involvement of the PI3K/Akt pathway.
- Utilized bioinformatics to predict miR-33a targets and validated PPAR-α as a target.
Main Results:
- miR-33a and its host gene SREBP2 were upregulated in activated Lx-2 cells.
- miR-33a expression correlated with TGF-β1-induced α1(I) collagen and α-SMA expression.
- Anti-miR-33a treatment increased PPAR-α expression and inhibited HSC activation and ECM production, partly via PI3K/Akt and PPAR-α.
Conclusions:
- miR-33a expression is elevated during liver fibrosis progression.
- Targeting miR-33a, potentially via anti-miR-33a, may be a therapeutic strategy for liver fibrosis.
- The mechanism involves modulation of HSC activation, ECM production, PI3K/Akt pathway, and PPAR-α.
Related Concept Videos
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
Cirrhosis II: Pathophysiology
PI3K/mTOR/AKT Signaling Pathway

